Trastuzumab Emtansine

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.

**Synonyms:** - ADO-Trastuzumab Emtansine - Ado Trastuzumab Emtansine - Immunoglobulin G1, Anti-(Human p185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide with N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine - Kadcyla - PRO 132365 - PRO-132365 - PRO132365 - RO5304020 - T-DM1 - TDM1 - TRASTUZUMAB EMTANSINE - Trastuzumab emtansine - Trastuzumab-DM1 - Trastuzumab-MCC-DM1 - Trastuzumab-MCC-DM1 Antibody-Drug Conjugate - Trastuzumab-MCC-DM1 Immunoconjugate